Hologic
Hologic Inc is an American medical technology company headquartered in Marlborough, Massachusetts, that was acquired by funds managed by Blackstone and TPG and delisted from the Nasdaq Stock Market in April 2026 in a take-private transaction valued at approximately $18.3 billion. Prior to the buyout, Hologic operated as a global leader dedicated primarily to women's health, developing, manufacturing, and supplying diagnostic products, medical imaging systems, and surgical devices. Its operations were organized across core segments including Diagnostics for molecular assays and cytology, Breast Health for 3D mammography and biopsy platforms, and GYN Surgical for minimally invasive uterine and gynecological procedures, alongside a smaller Skeletal Health unit that was previously divested. Revenue was heavily driven by recurring sales of proprietary test cartridges, consumables, and multi-year service contracts tied to a large global installed base of automated Panther testing instruments and imaging systems. The company served hospital networks, independent clinical laboratories, outpatient surgical centers, and healthcare providers across North America, Europe, and the Asia-Pacific region. Employing roughly seven thousand people and generating approximately four billion dollars in annual revenue, Hologic continues operating as a privately held enterprise following the buyout.
3 of the funds FundTelligence covers report a position in Hologic.
- Legal name
- Hologic Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
Funds holding Hologic
- Mercer Passive Global Equity Fund — Mercer · 0.02 % (full portfolio disclosed, December 2025)
- MGI Global Equity Fund — Mercer · 0.01 % (full portfolio disclosed, December 2025)
- DWS Invest CROCI World Value — DWS · 0.0 % (full portfolio disclosed, June 2026)